It has been reported that diphenyleneiodonium have therapeutic potential for NADPH oxidase-containing human colon cancers in vivo and that at least part of their antineoplastic mechanism of action may be related to targeting Nox1 [35]. The gene discussed is FMO5; the disease is malignant colon neoplasm.